Pyramid Analytics & PwC Germany Sign Partnership Agreement
28.2.2023 12:00:00 EET | Business Wire | Press release
Pyramid Analytics and the auditing and consulting firm PwC Germany have signed a partnership agreement for the distribution and implementation of the Pyramid Decision Intelligence Platform. PwC Germany will implement Pyramid's pioneering decision intelligence platform at companies and organizations across German-speaking countries in the financial and ESG (environmental, social and governance) sectors.
Pyramid offers a market-leading holistic data analytics platform that combines business analytics, data preparation and data science. As a full service provider, PwC Germany's Business Analytics service line provides both the functional conception and the technical implementation of customized decision support and analytical information systems. Specific application areas are corporate planning and simulation solutions as well as complex analytical reporting applications.
Enterprise-wide Decision Intelligence
The Pyramid Decision Intelligence Platform combines data preparation, business analytics and data science with AI guidance in a single integrated platform. This eliminates the need to use tools from multiple vendors, resulting in lower licensing costs and greatly simplifying enterprise-wide data management. Lower total cost of ownership (TCO), rapid adoption, fast and direct access to all available data, and industry-leading user adoption simultaneously accelerate value creation, growth, and innovation. The Pyramid Decision Intelligence Platform can be deployed on-premise, in private and public clouds, embedded, or through managed services providers (MSPs).
Thomas Hampel, Partner Business Analytics at PwC Germany, comments on the partnership: "The Pyramid Decision Intelligence Platform is an innovative and powerful BI and Analytics platform. The fact that the platform connects to a wide variety of database sources is particularly relevant. This is of great importance against the background of increasing cloud transformation and the accompanying fragmentation of our customers' technology landscapes. Another plus point of the all-in-one solution is that, in addition to a wealth of reporting formats and media, it also has sophisticated data science and analytics capabilities and offers powerful SAP BW interoperability."
"We are very excited to partner with PwC Germany," adds Bill Clayton, VP of Global Partner Sales at Pyramid Analytics. "With deep domain and process expertise coupled with the extensive implementation experience of PwC Germany's Business Analytics service line, together we are able to provide our customers with an end-to-end implementation of analytic decision support systems from a single source."
About PwC
At PwC, our purpose is to build trust in society and solve important problems. We’re a network of firms in 152 countries with over 327,000 people who are committed to delivering quality in assurance, advisory and tax services.
The term PwC refers to the PwC network and/or one or more of the legally independent network companies. Further details at www.pwc.com/structure.
In this document, “PwC” refers to PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft, which is a member firm of PricewaterhouseCoopers International Limited (PwCIL). Each member firm of PwCIL is a separate and independent legal entity.
About Pyramid Analytics
Pyramid is what’s next in analytics. The award-winning Pyramid Decision Intelligence Platform delivers insights for making faster, optimized decisions by providing direct access to any data, enabling governed self-service for any person, and meeting any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. This enables a strategic, enterprise-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005246/en/
Contact information
Alex Izza
Resonance
Tel.: +44 7591 899654
E-Mail: pyramidanalytics@resonancecrowd.com
Pete Vomocil
Senior Vice President, Global Marketing, Pyramid Analytics
Tel.: +1 541-520-2726
E-Mail: peter.vomocil@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-making. However, compared to Riskified’s agentic commerce pulse survey in Q4 2025, consumer sentiment has shifted, with growing concerns around fraud, security, and accountability slowing the path to fully autonomous, agent-driven transactions. Key findings from th
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 15:00:00 EEST | Press release
Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environment. The findings highlight a growing disconnect between ambition and execution. Cross-border transactions are expected to form a significant portion of deal pipelines, with 47% of respondents expecting them to account for between 26% and
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼ REZZAYO ® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 14:43:00 EEST | Press release
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,1 representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable efficacy is expected. The ReSPECT study met its primary endpoint for US Food and Drug Administration (FDA) and European Medicines
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 14:00:00 EEST | Press release
Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and self-adhesive product solutions. Operating across six global regions and serving both complex industrial and fast-moving consumer markets, t
vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 14:00:00 EEST | Press release
vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom